Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 19/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17477499 | 0.88 | GRM2 (0.54) | GRM2 | |
| SCHEMBL17477350 | 0.87 | GRM2 (0.44) | GRM2 | |
| SCHEMBL17477329 | 0.83 | GRM2 (0.57) | GRM2 | |
| SCHEMBL17477393 | 0.83 | GRM2 (0.51) | GRM2 | |
| SCHEMBL17477366 | 0.82 | GRM2 (0.58) | GRM2 | |
| SCHEMBL17490716 | 0.81 | GRM2 (0.52) | GRM2 | |
| SCHEMBL17485498 | 0.80 | GRM2 (0.51) | GRM2 | |
| SCHEMBL17477478 | 0.80 | GRM2 (0.55) | GRM2 | |
| SCHEMBL17477388 | 0.79 | GRM2 (0.57) | GRM2 | |
| SCHEMBL17477525 | 0.79 | GRM2 (0.57) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174883-B1 | 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-24 | — | — | EP | disclosed |
| US-20180258096-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-13 | — | — | US | disclosed |
| US-10005785-B2 | Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-10005785-B2 | Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-10005785-B2 | Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-20170217971-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-03 | — | — | US | disclosed |
| US-20170217971-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-03 | — | — | US | disclosed |
| US-20170217971-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-03 | — | — | US | disclosed |
| EP-3174883-A1 | 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceutica, N.V. (BE) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016395-A1 | 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180258096-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM5, GRM1 | GRM2 1/4885PDE4A 1157/4885PDE4B 977/4885 |
| US-20170217971-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM5, GRM1 | GRM2 1/4885PDE4A 1323/4885PDE4B 1124/4885 |
| US-10005785-B2 | Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors | GRM2, GRM5, GRM1 | GRM2 1/4885PDE4A 1473/4885PDE4B 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.